Redhill Biopharma RDHL

NAS: RDHL | ISIN: US7574681034 12/11/2024

7,180 USD (-9,00%)

(-9,00%) 12/11/2024

Grafiek Redhill Biopharma

Grafiek Redhill Biopharma

1 dag1d -9,00%
1 week1w -13,60%
1 maand1m -10,03%
3 maanden3m 1.856,94%
6 maanden6m 1.448,41%
1 jaar1j 2.216,13%
5 jaar5j 15,25%

Redhill Biopharma in het nieuws

Toon enkel gratis nieuws

9 september 2024 · RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines · Persbericht

5 september 2024 · RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement · Persbericht

3 september 2024 · New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality · Persbericht

29 augustus 2024 · RedHill Biopharma Announces First Half 2024 Business Highlights · Persbericht

26 augustus 2024 · RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma · Persbericht

21 augustus 2024 · Talicia® Launched in the United Arab Emirates · Persbericht

19 augustus 2024 · RedHill Announces Positive Obesity and Diabetes Results with Opaganib · Persbericht

16 augustus 2024 · RedHill Biopharma Announces Plan to Implement ADS Ratio Change · Persbericht

1 augustus 2024 · Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease · Persbericht

22 juli 2024 · RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien · Persbericht

Profiel Redhill Biopharma

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

CEO: Dror Ben-Asher

Werknemers: 150

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe